Probiotic Strain Fights H. pylori in Gut Microbiome Study
A new PLOS ONE study finds Lactobacillus casei HY001 inhibits H. pylori growth and reduces gastric inflammation, with implications for gut microbiome health.
A newly published study has found that a specific strain of Lactobacillus casei — designated HY001 — can inhibit the growth of Helicobacter pylori, reduce its urease activity, and disrupt the bacteria's ability to colonise the stomach lining. Published in PLOS ONE on 14 May 2026, the research draws on both laboratory and animal experiments, offering new evidence that targeted probiotics may play a meaningful role in combating one of the world's most prevalent gastric infections.
Why This Matters for Gut Health in the UK
H. pylori infects an estimated half of the global population and is a leading cause of gastritis, peptic ulcers, and gastric cancer. In the UK, the infection remains a significant public health concern, with NHS pathways typically relying on a combination of antibiotics and proton pump inhibitors — a regimen increasingly undermined by antibiotic resistance. Growing interest in the gut-brain connection and the broader microbiome UK research landscape has intensified the search for complementary, non-antibiotic strategies to manage gastric infections and restore microbial balance.
What the Study Found
According to the researchers, L. casei HY001 significantly inhibited the growth of H. pylori SS1, decreased urease activity, and demonstrated strong co-aggregation properties — meaning it physically clumped with the pathogen, potentially limiting its ability to adhere to the stomach wall. The study also found that the probiotic reduced gastric inflammation and helped restore gut microbiota disrupted by H. pylori infection in animal models. These multimodal effects suggest the strain works through several simultaneous mechanisms rather than a single pathway, the researchers reported.
What This Means for Probiotic and Microbiome Research
For those interested in how to improve gut health naturally, these findings add to a growing body of evidence that specific probiotic strains — rather than broad-spectrum supplements — may offer targeted therapeutic benefit. The study's dual in vitro and in vivo approach strengthens confidence in the results, though the researchers stopped short of recommending clinical application without further human trials. Scientists working on microbiome UK programmes will likely view this as a promising signal warranting follow-up in controlled human studies.
The research underscores a broader scientific shift: understanding the gut not merely as a digestive organ, but as an ecosystem whose microbial composition has wide-ranging implications for health — including, via the gut-brain connection, neurological and psychological wellbeing. As UK microbiome research continues to expand through institutions and initiatives examining the British diet gut health relationship, studies like this offer a precise, mechanistic contribution to the field.
You might also like
- 7 Natural Ways to Boost GLP-1 and Gut Health
- How to Build Muscle as an Ectomorph (Without Ruining Your Gut Health)
- Low FODMAP Grocery List for Gut Health UK
96 Bacterial Strains. Two Shots a Day.
GOODIE is an award-winning fermented drink with 96 live bacterial strains — more than any yogurt or kombucha — never pasteurised, clinically tested, and 8 in 10 users felt less bloating within 14 days. Curious?